Tumor Cell Vaccines

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 601)


This chapter reviews the history of tumor cell vaccines, both autologous and allogeneic, as well as adjuvants used with tumor cell vaccines. The chapter discusses various tumor cell modifications that have been tested over the years. The immune response to tumor vaccines is briefly described, as are some methods of immune monitoring after vaccine therapy. Finally, there is a description of various tumor cell-based vaccines that have been tested in clinical trials.


Cancer Vaccine Cell Vaccine Autologous Tumor Cell Active Specific Immunotherapy Allogeneic Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Antonia, S.J., Seigne, J., Diaz, J., Muro-Cacho, C., Extermann, M., Farmelo, M.J., Friberg, M., Alsarraj, M., Mahany, J.J., Pow-Sang, J., Cantor, A. and Janssen, W. (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167, 1995–2000.CrossRefPubMedGoogle Scholar
  2. Arroyo, P.J., Bash, J.A., Wallack, M.K., Arroyo, P.J., Bash, J.A. and Wallack, M.K. (1990) Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol. Immunother. 31, 305–311.CrossRefPubMedGoogle Scholar
  3. Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature 392, 245–252.CrossRefPubMedGoogle Scholar
  4. Bash, J.A. (1993) Active specific immunotherapy of murine colon adenocarcinoma with recombinant vaccinia/interleukin-2-infected tumor cell vaccines. Ann. NY Acad. Sci. 690, 331–333.CrossRefPubMedGoogle Scholar
  5. Berd, D. (2004) M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev. Vaccines 3, 521–527.CrossRefPubMedGoogle Scholar
  6. Bluestone, J.A. (1998) Cell fate in the immune system: decisions, decisions, decisions. Immunol. Rev. 165, 5–12.CrossRefPubMedGoogle Scholar
  7. Bronte, V., Carroll, M.W., Goletz, T.J. Wang, M., Overwijk, W.W., Marincola, F., Rosenberg, S.A., Moss, B. and Restifo, N.P. (1997) Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Nat. Acad. Sci. USA 94, 3183–3188.CrossRefPubMedGoogle Scholar
  8. Bystryn, J.C. (1993) Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann. of the NY Acad. Sci. 690, 190–203.CrossRefGoogle Scholar
  9. Bystryn, J.C., Henn, M., Li, J. and Shroba, S. (1992a) Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res. 52, 5948–5953.PubMedGoogle Scholar
  10. Bystryn, J.C., Oratz, R., Roses, D., Harris, M., Henn, M. and Lew, R. (1992b) Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69, 1157–1164.CrossRefPubMedGoogle Scholar
  11. Colombo, M.P. and Forni, G. (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15, 48–51.CrossRefPubMedGoogle Scholar
  12. Colombo, M.P. and Rodolfo, M. (1995) Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Cancer Immunol. Immunother. 41, 265–270.CrossRefGoogle Scholar
  13. Durrant, L.G. and Spendlove, I. (2003) Cancer vaccines entering phase III clinical trials. Expert Opin. Emerg. Drugs 8, 489–500.CrossRefPubMedGoogle Scholar
  14. Halpern, B.N., Biozzi, G., Stiffel, C. and Mouton, D. (1966) Inhibition of tumour growth by administration of killed Corynebacterium parvum. Nature 212, 853–854.CrossRefPubMedGoogle Scholar
  15. Hanna, M.G., Jr., Hoover ,H.C., Jr., Vermorken, J.B., Harris, J.E. and Pinedo, H.M. (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19, 2576–2582.CrossRefPubMedGoogle Scholar
  16. Hom, S.S., Schwartzentruber, D.J., Rosenberg, S.A. and Topalian, S.L. (1993) Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J. Immunother. 13, 18–30.CrossRefGoogle Scholar
  17. Hsueh, E.C., Famatiga, E., Gupta, R.K., Qi, K. and Morton, D.L. (1998) Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann. Surg. Oncol. 5, 595–602.CrossRefPubMedGoogle Scholar
  18. Itoh, K., Platsoucas, C.D. and Balch, C.M. (1988) Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168, 1419–1441.CrossRefPubMedGoogle Scholar
  19. Jaffee, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann, M., Coleman, J., Grochow, L., Donehower, R.C., Lillemoe, K.D., O’Reilly, S., Abrams, R.A., Pardoll, D.M., Cameron, J.L. and Yeo, C.J. (2001) Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145–156.PubMedGoogle Scholar
  20. Johnston, D., Rouby, S. and Bystryn, J.C. (1994) Identification of melanoma cell surface antigens immunogenic in mice. Cancer Biother. 9, 29–38.PubMedGoogle Scholar
  21. Klein, G., Sjogren, H.O., Klein, E. and Hellstrom, K.E. (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561–1572.PubMedGoogle Scholar
  22. Kusumoto, M., Umeda, S., Ikubo, A., Aoki, Y., Tawfik, O., Oben, R., Williamson, S., Jewell, W. and Suzuki, T. (2001) Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 50, 373–381.CrossRefPubMedGoogle Scholar
  23. Leach, D.R., Krummel, M.F. and Allison, J.P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736.CrossRefPubMedGoogle Scholar
  24. Livingston, P.O., Albino, A.P., Chung, T.J. Real, F.X., Houghton, A.N., Oettgen, H.F. and Old, L.J. (1985) Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55, 713–720.CrossRefPubMedGoogle Scholar
  25. Marshall, M. (2003) Development of therapeutic cancer vaccines conference, 27–29 April 2003. Cancer Immunol. Immunother. 52, 648–654.CrossRefPubMedGoogle Scholar
  26. McCune, C.S., O’Donnell, R.W., Marquis, D.M. and Sahasrabudhe, D.M. (1990) Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32, 62–66.CrossRefPubMedGoogle Scholar
  27. Mitchell, M.S. (1998) Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 25, 623–635.PubMedGoogle Scholar
  28. Mitchell, M.S. (2002a) Cancer vaccines, a critical review—Part I. Curr. Opin. Invest. Drugs 3, 140–149.Google Scholar
  29. Mitchell, M.S. (2002b) Cancer vaccines, a critical review—Part II. Curr. Opin. Invest. Drugs 3, 150–158.Google Scholar
  30. Morton, D.L., Hsueh, E.C., Essner, R., Foshag, L.J., O’Day, S.J., Bilchik, A., Gupta, R.K., Hoon, D.S., Ravindranath, M., Nizze, J.A., Gammon, G., Wanek, L.A., Wang, H.J. and Elashoff, R.M. (2002) Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg, 236, 438–448.CrossRefPubMedGoogle Scholar
  31. Pardoll, D.M. (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399–415.CrossRefPubMedGoogle Scholar
  32. Prehn, R.T. (1975) Relationship of tumor immunogenicity to concentration of the oncogen. J. Nat. Cancer Inst. 55, 189–190.PubMedGoogle Scholar
  33. Prehn, R.T. and Main, J.M. (1957) Immunity to methylcholanthrene-induced sarcomas. J. Nat. Cancer Inst. 18, 769–778.PubMedGoogle Scholar
  34. Sahasrabudhe, D.M., deKernion, J.B., Pontes, J.E., Ryan, D.M., O’Donnell, R.W., Marquis, D.M., Mudholkar, G.S. and McCune, C.S. (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Mod. 5, 581–594.PubMedGoogle Scholar
  35. Salgaller, M.L. and Lodge, P.A. (1998) Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68, 122–138.CrossRefPubMedGoogle Scholar
  36. Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F.S., Jaklitsch, M., Mentzer, S., Swanson, S., Lukanich, J., Bueno, R., Wain, J., Mathisen, D., Wright, C., Fidias, P., Donahue, D., Clift, S., Hardy, S., Neuberg, D., Mulligan, R., Webb, I., Sugarbaker, D., Mihm, M. and Dranoff, G. (2003) Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624–630.CrossRefPubMedGoogle Scholar
  37. Schultz, N., Oratz, R., Chen, D., Zeleniuch-Jacquotte, A., Abeles, G. and Bystryn, J.C. (1995) Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 13, 503–508.CrossRefPubMedGoogle Scholar
  38. Sondak,V.K. and Sosman, J.A. (2003) Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin. Cancer Biol. 13, 409–415.CrossRefPubMedGoogle Scholar
  39. Van Epps, D. (2004) Characterization of polyvalent allogeneic vaccines. Dev. Biol. 116, 79–90.Google Scholar
  40. Vermorken, J.B., Claessen, A.M., van Tinteren, H., Gall, H.E., Ezinga, R., Meijer, S., Scheper, R.J., Meijer, C.J., Bloemena, E., Ransom, J.H., Hanna, M.G., Jr. and Pinedo, H.M. (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353, 345–350.CrossRefPubMedGoogle Scholar
  41. White, P.J. and Shackelford, P.G. (1983) Edward Jenner, MD, and the scourge that was. Am. J. Dis. Child. 137, 864–869.PubMedGoogle Scholar
  42. Wiemann, B. and Starnes, C.O. (1994) Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64, 529–564.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Interdisciplinary Oncology H. Lee Moffitt Cancer Center & Research InstituteUniversity of South FloridaTampaUSA

Personalised recommendations